{"id":"W2332763467","doi":"10.1016/j.clml.2015.07.588","title":"A Phase 1/2 Trial of the Insulin Growth Factor 1 Receptor (IGF-1R) inhibitor, Linsitinib in Combination with Bortezomib (BTZ) and Dexamethasone (Dex) for the Treatment of Relapsed/Refractory Multiple Myeloma (MM)","year":2015,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Jewish General Hospital; Hôpital Maisonneuve-Rosemont; Princess Margaret Cancer Centre","funders":"","keywords":"Bortezomib; Dexamethasone; Pharmacology; Multiple myeloma; Insulin-like growth factor; Medicine; Refractory (planetary science); Clinical trial; Proteasome inhibitor; Receptor; Internal medicine; Oncology; Growth factor; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00172892,0.002376883,0.002747579,0.0006813756,0.0005675123,0.001434871,0.001188998,0.001939542,0.004693632],"category_scores_gemma":[0.001171068,0.0008491708,0.001659223,0.0005999652,0.001439545,0.001370526,0.0004427531,0.005574234,0.001292572],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001524113,"about_ca_system_score_gemma":0.002045876,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002142158,"about_ca_topic_score_gemma":0.005645612,"domain_scores_codex":[0.9995828,0.0001650918,0.00001657875,0.00009769433,0.00003791897,0.00009997599],"domain_scores_gemma":[0.9993752,0.0001001834,0.00008362427,0.00004362658,0.00003235911,0.0003650117],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.877943,0.03738163,0.001571374,0.0005984906,0.0009740575,0.0001876089,0.0001909996,0.001449191,0.01669478,0.0003395923,0.005741276,0.05692808],"study_design_scores_gemma":[0.8576476,0.1354247,0.002646631,0.00002689056,0.0002691543,0.000156882,0.00003195315,0.0005836606,0.001006927,0.0002224239,0.001961414,0.00002168377],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9767935,0.006227355,0.001015302,0.00268982,0.000766812,0.004415822,0.002862184,0.0003442821,0.004885059],"genre_scores_gemma":[0.9680911,0.005141506,0.004880878,0.003892515,0.0006248706,0.004856534,0.006021728,0.0001150547,0.006375835],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004693632,"threshold_uncertainty_score":0.01570177,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07643165159987207,"score_gpt":0.3600412260199811,"score_spread":0.283609574420109,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}